Nuclear data for medical applications : an overview by Qaim, S. M.
Radiochim. Acta 89, 189–196 (2001)
 by Oldenbourg Wissenschaftsverlag, München
Nuclear data for medical applications: an overview
By S. M. Qaim∗
Institut für Nuklearchemie, Forschungszentrum Jülich GmbH, D-52425 Jülich, Germany
(Received June 19, 2000; accepted in revised form September 26, 2000)
Nuclear reaction / Cross section / Decay data / Diagnosis /
Therapy / Data files
Summary. A brief introduction to nuclear data in medicine
is given. The choice of a radioisotope for medical application
demands an accurate knowledge of radioactive decay data.
Short-lived single photon and β+-emitters are preferred for
diagnostic investigations, and longer-lived corpuscular radia-
tion emitting radioisotopes for endoradiotherapy. The nuclear
reaction cross section data, on the other hand, are needed
for optimising the production routes. Besides radioactive iso-
topes, the use of ionising radiation in therapy is discussed.
External radiation therapy has achieved an important place in
medicine. The role of nuclear data is briefly discussed; they
are needed for radiation dose calculations. The hitherto rather
neglected activation products in proton therapy are considered.
The methodology of development of a nuclear data file for
medical applications is outlined.
Introduction
Soon after the discovery of radioactivity by H. Becquerel
in 1896, thoughts started developing about a possible appli-
cation of this phenomenon in medicine. It was George de
Hevesy, a Hungarian born physical chemist, who first in-
troduced radioactive tracers in biology. This concept was
followed by several other scientists. Tracer applications in
general, and nuclear medicine in particular, received an im-
petus through the development of nuclear reactors and their
use in the production of a large number of radioisotopes. The
availability of organic compounds labelled with β−-emitting
radioisotopes like 3H, 14C, 32P, 35S, 125I, etc. contributed ap-
preciably to the development of biochemistry via in vitro
methods. Also for in vivo investigations a variety of ra-
diopharmaceuticals labelled with γ-emitting radioisotopes
like 18F, 51Cr, 99mTc, 131I, etc. were introduced. However,
for many diagnostic studies, neutron deficient radioisotopes
appeared to be more suitable. Continuous efforts have there-
fore been underway to develop cyclotrons and accelerators
devoted to the production of those radioisotopes. Today, the
radioisotope production technology is well developed and
both reactors and cyclotrons are utilized for production pur-
poses. The proper use of nuclear data constitutes an integral
part of any production process. The field of diagnostic nu-
clear medicine (i.e. diagnostic studies using radioactive trac-
ers) is flourishing [cf. 1, 2] and demands new radioisotopes
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and radiopharmaceuticals for investigating various biochem-
ical phenomena.
Radioactivity is unique in its properties since it can con-
tribute to both diagnosis and therapy, the former by virtue
of its high detection sensitivity and the latter through the
biological effects of radiation. Depending on its decay char-
acteristics and use, a radioisotope can therefore be classified
as a diagnostic or a therapeutic radionuclide. The thera-
peutic radioisotopes, especially those suitable for endora-
diotherapy, have been gaining enhanced attention in recent
years [cf. 1, 2]. There is considerable need of nuclear data
research relevant to the production and application of those
radioisotopes.
In addition to radioactive isotopes, ionising radiation in
general has found many applications in therapy. Besides
photons, electrons and neutrons, high-energy charged par-
ticles like protons, 4He and heavy ions (14N, 22Ne, etc.) have
been finding increasing use in the treatment of various types
of tumours and malignant diseases. The data needs in this re-
gard are extensive. Also modelling of radiation transport is
important to be able to estimate the radiation dose properly.
In this introductory article the role of nuclear data in both
diagnosis and therapy is outlined. The discussion is grouped
together under “radioisotope programmes” and “external ra-
diation therapy”. Finally, the development of a nuclear data
file for medical applications is considered.
Significance of nuclear data in medically related
radioisotope programmes
In nuclear medicine programmes involving radioisotopes,
both radioactive decay and nuclear reaction cross section data
are needed. We briefly discuss the two types of data below.
Radioactive decay data
These data allow a calculation of the radiation dose to the pa-
tient caused by the administered radioactivity. The method-
ology used throughout the world for internal dose calcula-
tions is provided by the Medical Internal Radiation Dose
Committee (MIRD) of the Society of Nuclear Medicine in
the United States and its many collaborators and consultants,
and is referred to as the “MIRD formalism”. According to
this formalism the dose is determined via the expression:
D¯ = 2.13c¯
∑
i
ni E¯iΦi ,
where
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c¯ is the cumulative concentration of activity (Bq · Teffln 2/kg),
ni the number of emitted particles or photons per decay,
E¯i the average energy of the emitted radiation,
Φi the part of the radiation absorbed in the organ, and
Teff the effective half-life of the radioisotope in the organ.
Several computerized versions of the MIRD formalism,
e.g. MIR-DOSE (a PC-based program) [3], are available.
The dose calculations help to decide whether the radioiso-
tope under study is suitable for diagnostic applications. The
underlying principle in all diagnostic investigations is that
the radiation dose to the patient should be as low as possible.
A second important aspect of radioactive decay data is re-
lated to the detection of the emitted radiation. With the ever-
increasing significance of emission tomography, viz. Sin-
gle Photon Emission Computed Tomography (SPECT) and
Positron Emission Tomography (PET), radioisotopes emit-
ting suitable radiation are in great demand. As regards thera-
peutic radioisotopes, a high radiation dose is deliberately de-
sired. For an accurate dose estimation, however, good radia-
tion detection possibility is required. With pure β−-emitters
(e.g. 32P, 90Y, etc.) the distribution of radioactivity cannot be
measured from outside the body. The dosimetry in the rel-
evant applications is therefore rather empirical. The decay
data are thus of great significance in the choice and appli-
cation of a radioisotope in medicine. Some of the important
types of relevant decay data are given in Table 1.
In general, the nuclear structure and decay data are well
known, and considerable efforts have been harnessed to es-
tablish data files and libraries [4–6]. As far as medical appli-
cations are concerned, the MIRD Committee has compiled
data for about 250 radionuclides, including decay schemes
and equilibrium dose constants [7]. In fact these data are the
basis for further nuclear medical work. However, it is not ex-
cluded that a radioisotope finds considerable use, although
some of its decay characteristics are not known well. Some
Type of data Quantities Main applications
Radioactive decay data – Half-life • Choice of the radioiso-
– α-, β-, γ-ray energies and tope for medical use
intensities (diagnosis, therapy)
– EC/β+ branching ratio
– IT, conversion coefficient • Internal radiation dose
– X-ray and Auger electron calculation
intensities
– Decay scheme
Nuclear reaction data Neutron data
– Scattering and capture • Reactor production of
cross sections radioisotopes
– Resonance integrals
– (n, charged particle)
reaction cross sections
– Fission yields
Charged particle data
– Reaction thresholds • Cyclotron production of
– Excitation functions radioisotopes
– Differential and integral
data
– Thin and thick target
yields
Table 1. Nuclear data relevant to medical ap-
plications of radioisotopes.
of the areas where deficiencies may exist include β−- and
γ-ray intensities, EC- and β+-decay branching, Auger elec-
tron spectra and intensities, etc. All those deficiencies lead
to some inaccuracy in the estimation of radiation dose and
quantitation of effect of ionising radiation.
Nuclear theory and systematics are sufficiently advanced
to predict decay data for normal nuclei with reasonable ac-
curacies. Only for light nuclei and for those far away from
the stability line the predictions are less certain. Still, in re-
cent years, two developing areas of nuclear medicine have
revealed some deficiencies in the existing decay data. One
pertains to endoradiotherapy (and brachytherapy) with ra-
dioisotopes emitting soft radiation, such as X-rays, Auger
electrons and low-energy β−- or β+-particles. The other
one pertains to PET studies with non-common longer-lived
β+-emitters. Accurate decay data (e.g. energies and inten-
sities of emitted radiation) can only be obtained if the ra-
dioisotope under investigation is available in a pure form
(through the choice of a proper production reaction and
chemical or mass separation). A recent example is furnished
by the potentially useful β+-emitter 120gI (T1/2 = 1.35 h).
Its β+-decay branching value was reported to be between
39 and 81%. Recent radiochemical studies [8] established
a value of 56± 3%. Thus, despite the huge body of de-
cay data available, it may be occasionally necessary to per-
form new and accurate measurements on some selected
radioisotopes.
Nuclear reaction data
These data are needed in radioisotope production pro-
grammes, mainly for optimisation of production routes.
Since radioisotopes are produced in reactors as well as at cy-
clotrons, both neutron and charged particle induced reaction
cross section data are required. The energy ranges involved
are rather broad. In the case of neutrons mostly thermal en-
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ergies and fission neutron spectrum are important, and in
charged particles, energy ranges extending from a few MeV
up to several hundred MeV. A summary of the reaction cross
section data needed in radioisotope production programmes
is given in Table 1. We briefly outline the importance of nu-
clear data in meeting some of the quality requirements of the
product.
In reactor production of radioisotopes, the most com-
monly used nuclear routes include (n, γ), (n,fission) and
(n,charged particle) processes. The (n, γ) reaction has gen-
erally a high cross section at thermal neutron energies,
so that the yield of the product is rather high. However,
a serious drawback of the process is the low specific radioac-
tivity which makes the radioisotope less suitable for medical
applications. The specific radioactivity can be improved
through various methods (cf. Qaim, this issue, contribution
on diagnostic radioisotopes). Nonetheless, in principle the
drawback remains. The fission process is a very suitable
method to produce a large number of radioisotopes in a “no-
carrier-added” form. The chemical processing involved,
however, is rather extensive. The (n,p) and (n, α) reaction
cross sections are generally low; these processes are there-
fore used to produce only a few radioisotopes in the light
mass element region. In general the nuclear data needed in
radioisotope production programmes are of integral nature
(e.g. fission neutron spectrum averaged cross sections) and
are mostly available in the evaluated neutron data libraries.
The cross section data base for the reactor production
of radioisotopes is well established. Only for some special
radioisotopes under development (e. g. those produced via
double neutron capture), new measurements and evaluations
may be necessary. As far as the predictive power of nuclear
theory and systematics is concerned, the low-energy (n, γ),
(n,p) and (n, α) reactions are described reasonably well by
the statistical model, and the fission yields are predicted with
good accuracies by the systematics.
In cyclotron production of radioisotopes, the reaction
cross section data play a very important role (for early re-
views [cf. 9, 10]). Due to rapid degradation of the projec-
tile energy in the target material, the energy range covered
within the target is relatively broad, and, since the reaction
cross section varies rather rapidly with energy, it is not ap-
propriate to adopt an average cross section over the whole
energy range. One needs rather the full excitation function
of the nuclear process to be able to calculate the yield with
a reasonable accuracy. A further important point is the num-
ber of competing reaction channels. At an incident projectile
energy of 20 MeV, for example, about six reaction chan-
nels with significant cross sections accur. With a view to
estimating the activity balance, it is imperative to know the
cross sections of all those processes. Production of radioiso-
topes may be carried out using protons, deuterons, 3He-
or α-particles. A knowledge of all the reaction cross sec-
tions is necessary. The demands on the data may thus be
extensive. In practice, however, only a few radioisotopes
are produced via reactions induced by particles other than
protons. The data requirements are therefore foreseeable.
At small-sized cyclotrons, low-energy reactions like (p,n),
(p, α), (d,n), (d, α), etc. are used. At higher energies, on
the other hand, (p,xn) reactions are commonly employed. In
some special cases, the (p,spall) process is applied.
From a given excitation function, the expected yield of
a product for a certain energy range (i.e. target thickness)
can be calculated using the expression:
Y = NL ·H
M
I(1− e−λt)
E2∫
E1
(
d E
d(ρx)
)−1
σ(E)d E ,
where NL is the Avogadro number, H the enrichment (or
isotopic abundance) of the target nuclide, M the mass num-
ber of the target element, I the projectile current,
(
dE
d(ρx)
)
the
stopping power, σ(E) the cross section at energy E, λ the de-
cay constant of the product and t the time of irradiation. The
calculated yield value represents the maximum yield which
can be expected from a given nuclear process.
The optimisation of a nuclear process for the produc-
tion of a radioisotope at a cyclotron involves a selection
of the projectile energy range that will maximise the yield
of the product and minimise that of the radioactive impuri-
ties. Whereas the non-isotopic impurities produced can be
removed by chemical separations, the level of isotopic im-
purities can be suppressed only using enriched isotopes as
target materials and/or by a careful selection of the particle
energy range effective in the target.
The radioisotope 123I (T1/2 = 13.2 h), a commonly em-
ployed halogen nuclide for labelling biomolecules for diag-
nostic studies using SPECT, for example, can be produced
via various routes. Its production via the 124Te(p,2n)123I re-
action furnishes a good example of the importance of nu-
clear data. In order to decrease the level of isotopic im-
purities in the 123I produced, it is essential to use highly
enriched 124Te as target material. However, due to the com-
peting 124Te(p,n)124I reaction it is not possible to eliminate
the 124I impurity completely, even if 124Te is 100% enriched.
Fig. 1, based on the excitation function measurements de-
scribed in [11, 12], shows that the suitable proton energy
range for the production of 123I is Ep = 25.0 → 18.0 MeV,
i.e. the energy of the incident protons should be selected as
25.0 MeV and the thickness of the tellurium target should
degrade the incident energy only to 18.0 MeV. Under these
conditions the yield of 123I at the end of bombardment (EOB)
amounts to 565 MBq/µAh and the level of 124I impurity in
123I to about 1%. If still a lower impurity level is desired, the
energy window would have to be further adjusted. Evidently,
Fig. 1. Excitation functions of 124Te(p,n)124I and 124Te(p, 2n)123I re-
actions. The suitable energy range for the production of 123I is Ep =
25.0→ 18.0 MeV (based on data reported in [11, 12]).
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it is necessary to know the excitation functions of the various
competing reactions accurately.
The radioactive impurities have a dual effect: firstly, they
adversely affect the line spread function in imaging and sec-
ondly, cause enhanced radiation dose to the patient. If the
amount of a longer-lived impurity is too high, it may jeop-
ardise the whole advantage of the short-lived radioisotope
used. It may then be necessary to look for an alternative
route of production for the desired radioisotope.
Besides isotopic impurities discussed above, in recent
years the awareness of isomeric impurities has also in-
creased. Several medically interesting research type ra-
dioisotopes have isomeric states which are rather disturbing.
A few examples are 94mTc (94gTc), 120gI (120mI), etc. The
isomeric impurities cannot be controlled through a care-
ful adjustment of the energy window (as mentioned above).
Since the isomeric cross section ratio is primarily dependent
on the type of reaction involved (for a review see [13]), it
is essential to investigate all the possible production routes
and then to choose the reaction and the energy range giv-
ing the best results. Obviously, nuclear data play here a very
important role.
The nuclear reaction cross section data relevant to the
production of the commonly used cyclotron radioisotopes
are fairly well known, and a recent IAEA-TECDOC [14],
prepared as an outcome of a Coordinated Research Pro-
gramme (CRP) on “Medical Radioisotope Production”, de-
scribes the recommended data in the desired energy ranges.
New measurements are generally required while searching
for an alternative route of production of a useful radioiso-
tope or while performing development work on a potentially
important radioisotope. The two fast developing areas of nu-
clear medicine mentioned above, viz. endoradiotherapy and
PET studies using longer-lived β+-emitters, demand consid-
erable amount of experimental nuclear data work.
As far as nuclear model calculations are concerned,
in the case of charged particle induced reactions, vary-
ing degree of success has been met. The cross sections
for the light mass target nuclei can hardly be described
by the model calculations. In the medium and heavy mass
regions, however, both the compound/precompound and
precompound/hybrid models (using, for example, the codes
STAPRE/GNASH and ALICE-IPPE, respectively) have
been partially successful. In general, a priori calculations do
not meet the accuracy requirements needed in radioisotope
production programmes. Experimental studies are thus often
necessary.
Significance of nuclear data in external radiation
therapy
External radiation therapy involves the use of electrons,
X-rays, high-energy γ-rays or hadrons (neutrons, protons,
heavy ions, etc.). The use of low-energy electrons (emitted
from radioactive sources or supplied by small accelerators),
X-rays (from conventional sources), high-energy electrons
(supplied by a LINAC) and high-energy photons (produced
as bremsstrahlung in the interactions of high-energy elec-
trons with heavy elements) constitutes conventional or stan-
dard therapeutic practice. The interactions involved repre-
sent well-understood phenomena in atomic physics, and the
data needed for both electron and photon therapy are well
documented. Only in the case of very high energy photons,
photonuclear processes like (γ, n), (γ, 2n), etc. may occur.
The energy and angular distributions of the emitted neutrons
are then of importance both from the viewpoint of radiation
transport and radiation shielding. Furthermore, some activa-
tion products may also be formed.
Two important considerations in radiation therapy are
the linear energy transfer (LET) and the relative biological
efficiency (RBE). Use of hadrons in comparison to conven-
tional therapy can have the advantage of a better physical
selectivity, i.e. an improved dose profile and a higher bi-
ological efficiency, corresponding to greater killing in the
tumour [cf. 15]. However, the various hadrons differ in their
properties. In Fig. 2 the depth-dose relationship of photons,
neutrons, protons and nitrogen ions are compared. Obvi-
ously neutrons and photons have a similar dose distribution
whereas for charged particles the dose increases with the
penetration depth, reaching a maximum value in the Bragg-
peak area. Neutrons do not exhibit this advanced physical
dose profile but differ in their RBE from photons. The ul-
timate aim of hadron therapy is to optimise both physical
and biological selectivity (cf. contributions by Jones and by
Wambersie, on the rationale of hadron therapy, this issue).
In ion therapy, both atomic and nuclear interactions are
involved, the contribution of the latter increasing with in-
creasing energy. The interactions of neutrons are somewhat
difficult to understand since they involve many nuclear phe-
nomena which cannot always be calculated in a reliable
manner.
In neutron therapy, cross sections are needed for the for-
mation of secondary neutrons, γ-rays and charged particles;
a very brief summary is given in Table 2. The data are re-
quired to estimate the absorbed dose in the patient. Informa-
tion on secondary neutrons and γ-rays is needed to calculate
radiation transport over large distances. The data on charged
Fig. 2. Depth dose distribution of γ-rays, neutrons, protons and nitro-
gen ions in tissue (adapted from [15]). The area around the maximum
dose in the case of charged particles is termed as “Bragg-peak” area.
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Type of data Quantities Main applications
Neutron data – Elastic and nonelastic • Calculation of neutron
cross sections spectra
– Secondary neutron and • Radiation transport calcu-
γ-ray emission (differen- lations
tial and double differential
cross sections)
– Charged particle (p, d, t,α) • Calculation of kerma
emission (differential and coefficients
double differential cross
sections)
– Activation cross sections • Determination of activity
balance
Proton data – Total nonelastic cross • Estimation of proton
sections beam depletion
– Neutron, charged particles • Calculation of energy
and γ-ray emission deposition and radiation
(differential and double transport
differential cross sections)
– Average energies for the
light ejectiles
– Product recoil spectra • Estimation of RBE
– Activation cross sections • Determination of activity
balance and extra dose
through decay
Table 2. Nuclear data relevant to hadron
therapy.
particle emission in fast neutron induced reactions are of
considerable interest for calculating the heat deposited in
the tissue. The effect is expressed in terms of kerma coeffi-
cient (kinetic energy released in matter). The accuracy of the
neutron induced cross sections is often estimated by a com-
parison of kerma coefficients derived from cross sections
with those obtained experimentally. If the cross sections give
a kerma coefficient that is in agreement with experimental
measurements, the confidence in the absorbed dose predic-
tions by a transport code is increased.
In proton therapy, cross sections are needed for the for-
mation of neutrons and γ-rays, and to some extent secondary
charged particles. This information is required to calculate
the radiation transport and radiation dose. A brief summary
of the data needed is given in Table 2. The major advantage
of this therapy is the capability to treat deep-lying tumours,
close to critical structures. This is possible mainly due to the
high selectivity of the Bragg-peak.
The heavy-ion beam therapy has been performed with
12C, 14N, 20Ne, 28Si and 40Ar ions, but currently only 12C
is used. However, this is a rather specialized technique and,
despite its great potential, has found so far only limited ap-
plication. Another therapeutic approach is represented by
the administration of a boron based compound and, after
its accumulation in the tumour containing organ, irradiation
via an external thermal (better epithermal) neutron source
(boron neutron capture therapy, BNCT). The nuclear pro-
cess 10B(n, α)7Li leads to the release of short-range, densely
ionising α-particles and the 7Li-recoils which cause the ther-
apeutic effect.
Spectral data
From the above discussion it is evident that in radiation ther-
apy primarily spectral data are needed. Besides total, elas-
tic and nonelastic scattering cross sections, the energy- and
angle-dependent emission spectra of γ-rays, neutrons and
charged particles are needed. Due to the large effort involved
in such studies, only a limited number of experimental data
sets for biologically important target elements are available.
A heavy reliance on theory is therefore obvious. Since the
accuracy requirements are not as stringent as in the case
of data for production of diagnostic radioisotopes, the data
predicted via nuclear model calculations are generally ac-
ceptable (cf. Chadwick, this issue).
The availability of medium-energy nuclear data for radi-
ation therapy has been discussed (cf. Haight, this issue). The
new needs arising in connection with newly emerging thera-
pies are under constant review [cf. 16, 17]. Recently a very
thorough group study on nuclear data for neutron and pro-
ton radiotherapy has been performed [18] under the auspices
of the International Commission on Radiation Units and
Measurements. The final report of the group [18] gives infor-
mation on neutron-induced nuclear reaction cross sections
and kerma coefficients up to 150 MeV, and proton-induced
cross sections up to 250 MeV. The energy range of neutrons
currently used in therapy extends to about 70 MeV. How-
ever, since higher energies may be used in the future, the
data are given up to 150 MeV. All the data were obtained by
a combination of experiment and theory. For this purpose,
use was made of the GNASH nuclear model code, which
incorporates theories for compound nucleus, preequilibrium
and direct interactions. Optical model calculations served to
determine total, total nonelastic and elastic scattering cross
sections.
In hadron therapy nuclear data are needed primarily
for the major isotopes of H, C, N, O, Al, Si, P, Ca, Fe,
Cu, W and Pb, the latter elements being collimator and
shielding materials. Most detailed information is needed for
the most important elements, with lesser information for
the others. The above mentioned report [18] follows this
strategy.
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Activation products
In general, the activation of tissue components is not very
serious and hence very few experimental studies have been
reported with regard to the formation of activation products
in neutron as well as proton therapy. In several special cases,
however, activation may not be negligible. We discuss some
of them below.
The interactions of fast neutrons with light mass nu-
clei lead to the formation of significant amounts of tri-
tium (T1/2 = 12.3 a). In a comprehensive study with 53 MeV
d(Be) neutrons it was shown [19] that the (n,t) cross sections
for the lightest elements are exceptionally large (between 10
and 400 mb). However, for elements with Z > 20 the triton
emission cross section is constant at about 5 mb. Another ac-
tivity observed was 7Be (T1/2 = 53.3 d); however, with the
cross section in the µb range [20]. In the medium mass
region several short- and long-lived products were also ob-
served with formation cross sections of 5 to 10 mb [19, 21].
Thus, except for tritium, the radioactive products formed in
neutron therapy may not be of much significance. The acti-
vation of shielding and collimator materials, however, may
be significant.
Comprehensive experimental studies on the formation of
activation products in proton induced reactions exist in the
literature [22–24]. However, the biologically relevant elem-
ents have not been investigated in detail. As regards proton
therapy, a few experimental studies have been performed in
the following four directions:
a) formation of short-lived β+-emitters, like 11C (T1/2 =
20.3 min), 13N (T1/2 = 10.0 min) and 18F (T1/2 =
110.0 min),
b) accumulation of 7Be (T1/2 = 53.3 d),
c) formation of medium mass activation products, like 22Na
(T1/2 = 2.6 a), 42K (T1/2 = 12.4 h), 48V (T1/2 = 16.0 d),
51Cr (T1/2 = 27.7 d), etc.,
d) accumulation of long-lived activity in collimators, like
54Mn (T1/2 = 312.2 d), etc.
From those studies it was concluded that the amount of
7Be accumulated is negligible [25]. Similarly the medium
mass activation products are also not significant [26]. The
activation of collimators, however, is appreciable [27] and
due precautions are necessary to protect the therapy person-
nel. The formation of short-lived β+-emitters is of consider-
able scientific interest. We therefore discuss it in more detail.
The formation cross sections of short-lived β+-emitters
are significant but the information available over the whole
energy range is rather scanty. The results of a recent meas-
urement and analysis on the formation of 11C (T1/2 =
20.3 min) from natN are shown in Fig. 3 [28]. Whereas ex-
tensive data exist up to 20 MeV [14], the data base at higher
energies is rather weak. Worth mentioning is that two ma-
jor contributing processes with different thresholds are in-
volved, viz. 14N(p, α)11C and 14N(p, 2p2n)11C. A small con-
tribution from the 15N(p, αn)11C reaction is also expected.
A theoretical calculation based on the precompound hy-
brid code ALICE-IPPE, incorporating α-particle emission,
is also shown in Fig. 3. Obviously the theory reproduces the
shape of the excitation function to some extent. However, the
magnitudes differ considerably.
Fig. 3. Excitation function of the natN(p, x)11C process. For a detailed
compilation of the data up to 20 MeV, see [14]. The diagram has been
adapted from [28].
The cross section data for the formation of short-lived
β+-emitters are important from two viewpoints: firstly, for
estimating the extra dose caused to the patient, and secondly,
for precise localisation of the dose distribution related to
therapy. Regarding the first, an estimate was done [28] for
liver as a source organ and a 200 MeV proton beam intersity
of 5 nA/cm2. The dose caused by 11C, 13N and 15O amounts
to approximately 500 mSv. Compared to a total radiation
dose of 2 Sv per therapy run, the enhancement in the radi-
ation dose through the decay of the short-lived β+-emitters
amounts to about 25%. Regarding the localisation of the
dose distribution, a combination of PET and proton therapy
is very promising [2]. Ideally, a simultaneous combination is
desired. However, technically it is very difficult since it in-
volves placing the therapy gantry and the PET machine very
close to each other (around the patient). A PET investigation
after the ion therapy (using 11C formed during the therapy
run) is more convenient and is practised at a few therapy
centres.
In summary, the activation cross sections may not be
of great significance in general radiation therapeutic appli-
cations. However, they are of considerable importance in
following some special therapeutic aspects.
Development of nuclear data file
The development of a nuclear data file for applications in-
volves several steps (Fig. 4). Experimental measurements
are done using both activation and spectral methods. It is im-
portant that the reported data contain a full description of
the experiment and various sources of errors together with
their estimated magnitudes. The second source of data is the
theory. Many nuclear models have been developed to pre-
dict unknown cross sections. Combining the experimental
data and theoretical results to obtain the best values of cross
sections is termed as “Evaluation”. An evaluator attempts to
derive “best” values from a set of incomplete experiments
Nuclear data for medical applications: an overview 195
Fig. 4. Steps in the development of a nuclear data file for applications.
and only partially reliable theoretical models. In the exer-
cise, often several adjustments have to be made. In energy
regions where few measurements exist, either due to lack
of facilities or due to experimental difficulties, a heavy re-
liance on theory is called for. The next step involves the
validation of evaluated data. This is generally done via some
benchmarks or integral tests. If large deviations occur, some
new measurements or calculations may be necessary. If the
validation experiments exhibit good reliability, some qual-
ity assurance tests, especially a description of errors and
definition of application limits are essential. The data thus
obtained are then considered as recommended data and con-
stitute a “file” for some special application.
Many types of data files exist in the literature and are co-
ordinated by one or more of the four major Nuclear Data
Centres, namely,
– NNDC, Brookhaven, USA,
– OECD-NEA Data Bank, Paris, France,
– IAEA Nuclear Data Section, Vienna, Austria,
– Nuclear Data Centre, Obninsk, Russia.
However, the majority of those files deal with the en-
ergy related data. As far as medical applications are con-
cerned, the efforts invested so far have been rather modest,
mostly directed to neutron therapy. The evaluation method-
ology (especially for data related to diagnostic applications)
is hitherto not as developed as in the case of energy related
data. The two most recent comprehensive efforts, one related
to diagnostic radioisotopes [14] and the other dealing with
the hadron therapy [18], are expected to fill the existing gaps
in data. Further detailed efforts are, however, essential to en-
hance our knowledge about several aspects of diagnosis and
therapy.
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